Venus Remedies Secures Marketing Nod for Three Oncology Drugs in Philippines and Saudi Arabia

7 Dec 2023 , 10:25 AM

Venus Remedies announced on Wednesday that it has obtained marketing authorization for three oncology drugs in the Philippines and Saudi Arabia. Regulatory approval was granted in the Philippines, the second-largest market in ASEAN, for the chemotherapy drug paclitaxel and zoledronic acid.

Saudi Arabia, the largest pharmaceutical market in the GCC region, has granted marketing authorization for another Venus Remedies oncology drug, bleomycin. The pharmaceutical market in the Philippines is projected to reach USD 4.917 billion by 2026, while the Saudi Arabian pharmaceutical market is expected to grow to USD 7.19 billion by 2028, as per data.

Saransh Chaudhary, President of Global Critical Care at Venus Remedies, highlighted the significance of these authorizations, stating that they endorse the company’s regulatory capabilities and unwavering commitment to quality.

Aditi K Chaudhary, President of the International Business wing, emphasized the strategic importance of these regulatory milestones for Venus Remedies’ international expansion strategy.

The company sees these approvals as a crucial step in contributing to healthcare improvement in South East Asia and the Middle East, serving as a prominent supplier of the three drugs in 15 countries.

For feedback and suggestions, write to us at [e-mail]